{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-028704","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2024-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.149683+00:00","generated_at":"2026-06-05T08:34:25.227353+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Iovance reports $444M net loss for 2023; Amtagvi approved and launched Feb 2024","bullets":["FDA approved Amtagvi (lifileucel) on Feb 16, 2024 — first T cell therapy for a solid tumor (advanced melanoma).","Net loss $444.0M ($1.89/share) for 2023 vs $395.9M ($2.49/share) in 2022; revenue $1.2M (first Proleukin sales).","Cash $346.3M at Dec 31, 2023; post Feb 2024 equity raise ~$485.2M, expected to fund operations into H2 2025.","~30 U.S. ATCs onboarded; ~50 expected by May 2024; at least 20 patients in process since approval.","MAA for EU expected H1 2024; UK and Canada submissions H2 2024; clinical hold on IOV-LUN-202 NSCLC trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-028704","json":"https://secwatch.observer/filing/0001104659-24-028704.json","markdown":"https://secwatch.observer/filing/0001104659-24-028704.md","text":"https://secwatch.observer/filing/0001104659-24-028704.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/tm247491d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T08:34:25.227353+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5fc26e93a2f0879babfb0e5ecdc5ffbe537c7ad3","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported fourth quarter ended December 31, 2023 results: net income Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, EPS $0.45 per share.","evidence_excerpt":"Net loss for the fourth quarter ended December 31, 2023, was $116.4 million, or $0.45 per share, compared to a net loss of $105.3 million, or $0.64 per share, for the fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2023"},{"label":"Net income","value":"Net loss for the fourth quarter ended December 31, 2023, was $116.4 million"},{"label":"EPS","value":"$0.45 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"7f346dbffc5803098027b9ed83a0270ddfe01b9f","claim":"IOVANCE BIOTHERAPEUTICS, INC. reported year ended December 31, 2023 results: net income Net loss for the year ended December 31, 2023 was $444.0 million, EPS $1.89 per share.","evidence_excerpt":"Net loss for the year ended December 31, 2023 was $444.0 million, or $1.89 per share, compared to a net loss of $395.9 million, or $2.49 per share, for the year ended Dec","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1425205/000110465924028704/0001104659-24-028704-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2023"},{"label":"Net income","value":"Net loss for the year ended December 31, 2023 was $444.0 million"},{"label":"EPS","value":"$1.89 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}